Founded in 2002 and based in Strasbourg, France, NovAliX is a drug discovery-focused CRO with several unique technologies. It employs nearly 200 researchers, with capabilities combining chemistry and biophysics.

NovAliX offers its clients original collaborative models and extensive services within the framework of research programs dedicated to drug discovery. Its ambition is to continue its development by both strengthening its internationalization and extending and integrating the new capabilities essential to the success of its clients' therapeutic research projects into its technologies and base of expertise.

For further information we invite you to visit the NovAliX website or to contact us at .